- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07601555
Body Composition, Functional Capacity, and Respiratory Muscle Endurance in Obesity With Restrictive Ventilatory Pattern
15 maggio 2026 aggiornato da: Buket AKINCI, Biruni University
Investigation of the Relationship Between Body Composition, Functional Capacity, and Respiratory Muscle Endurance in Individuals With Obesity and a Restrictive Ventilatory Pattern
This observational cross-sectional study aims to examine the relationship between body composition, functional capacity, and respiratory muscle endurance in individuals with obesity and a restrictive ventilatory pattern.
A total of 100 adults aged 25-60 years with a body mass index (BMI) ≥30 kg/m² and restrictive pulmonary function findings will be enrolled.
Participants will evaluate body composition assessment using bioelectrical impedance analysis, pulmonary function testing by spirometry, respiratory muscle strength and endurance measurements, and functional capacity evaluation using the Six-Minute Walk Test (6MWT).
The aim of this study is to evaluate the relationships between stem cell count (SCC), a novel anthropometric indicator called WWI, trunk muscle mass, and functional capacity in obese individuals with a restrictive ventilatory pattern.
Panoramica dello studio
Stato
Non ancora reclutamento
Condizioni
Intervento / Trattamento
Tipo di studio
Osservativo
Iscrizione (Stimato)
100
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Contatto studio
- Nome: Buket Akinci, Prof. Dr.
- Numero di telefono: +90 505 6415692
- Email: bakinci@biruni.edu.tr
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Adulto
Accetta volontari sani
Sì
Metodo di campionamento
Campione non probabilistico
Popolazione di studio
Obese Individuals with Restrictive Ventilatory Pattern
Descrizione
Inclusion Criteria:
- Individuals aged between 25 and 60 years
- Individuals with a body mass index (BMI) ≥ 30 kg/m² according to the World Health Organization (WHO) classification
- Individuals demonstrating a restrictive ventilatory pattern (FVC < 80% predicted)
- Individuals who voluntarily agree to participate in the study
Exclusion Criteria:
- Individuals with a Charlson Comorbidity Index (CCI) score of 3 or higher
- Individuals with uncontrolled arrhythmia, hypertension, heart failure, diabetes mellitus, or unstable angina pectoris
- Individuals with cooperation impairments, orthopedic, or neurological conditions that may interfere with assessment or treatment
- Individuals with a history of lower extremity injury or surgery within the last six months
- Individuals diagnosed with diabetes mellitus who have complications such as nephropathy, retinopathy, or neuropathy
- Individuals with concomitant chronic respiratory disease
- Individuals with acute infection
- Individuals with middle ear pathologies (e.g., tympanic membrane rupture or otitis)
- Individuals with a history of spontaneous or trauma-related pneumothorax
- Current smokers
- Pregnant individuals
- Individuals with a STOP-Bang score of 3 or higher
- Individuals currently participating in a structured weight-loss diet program or receiving medical treatment for weight loss during the assessment period
- Individuals who have undergone endoscopic intervention and/or bariatric surgery within the last year
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Obese Individuals with Restrictive Ventilatory Pattern
|
Participants will undergo a comprehensive assessment including pulmonary function testing using spirometry, body composition analysis using bioelectrical impedance analysis (BIA), respiratory muscle strength and endurance evaluation, and functional capacity assessment with the Six-Minute Walk Test (6MWT).
Anthropometric measurements including body weight, height, waist circumference, hip circumference, and waist-to-height ratio will also be recorded.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Functional capacity
Lasso di tempo: Day 1
|
Participants' exercise capacity will be assessed using the Six-Minute Walk Test (6MWT) according to the American Thoracic Society (ATS) guidelines with the Spiropalm 6MWT system (Cosmed, Italy) (ATS, 2002).
The test will be performed in a 30-meter indoor corridor following a minimum 10-minute rest period.
Heart rate, blood pressure, oxygen saturation, dyspnea, and leg fatigue levels will be recorded before and after the test.
Participants will be instructed to walk as fast as possible for six minutes and may rest or terminate the test if severe symptoms occur.
Total walking distance will be recorded in meters, and any interruptions or symptoms during the test will be documented.
|
Day 1
|
|
Respiratory Muscle Endurance
Lasso di tempo: Day 1
|
Participants' respiratory muscle endurance will be assessed using an inspiratory muscle training device (POWERbreathe® K-Series K3, POWERbreathe International Ltd, UK).
Measurements will be performed in a seated position with a nose clip applied and the device placed in the mouth.
The assessment will be conducted using an incremental threshold loading protocol.
At the beginning of the test, the threshold pressure will be set at 20% of the participant's maximal inspiratory pressure (MIP).
Participants will be instructed to complete 30 breaths over a two-minute period.
Individuals who tolerate this level will progress to subsequent stages with gradually increasing loads of 40%, 60%, 80%, and 100% of MIP, respectively.
Oxygen saturation and heart rate will be recorded before and after the test using a pulse oximeter.
Participants will also be informed that they may remove the device from their mouth and terminate the test at any time in the event of any discomfort or adverse symptoms.
|
Day 1
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Body fat mass
Lasso di tempo: Day 1
|
Participants' body fat mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).
Participants will be informed about the test protocol and instructed to fast for 8-12 hours before the assessment, arrive with an empty bladder, and avoid fluid intake, food consumption, and vigorous physical activity prior to testing.
Measurements will be performed during daytime at a room temperature of 25°C.
Participants will be assessed while clothed and barefoot after removing their shoes, socks, and all metal accessories.
|
Day 1
|
|
Forced vital capacity (FVC)
Lasso di tempo: Day 1
|
Forced vital capacity (FVC) will be evaluated using a Pulmonary Function Test (PFT) in accordance with the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria, utilizing the "COSMED Spiropalm 6MWT" device (COSMED, Italy) and its integrated PFT software (ATS & ERS, 2002).
Assessments will be performed in a seated position with back support.
To minimize the risk of infection, a disposable mouthpiece and filter will be used for each participant.
Values will be recorded both in liters and as percentages (%) of predicted values.
Measurements will be repeated three times, and the best value meeting the measurement standards will be recorded.
|
Day 1
|
|
Ventilation (VE)
Lasso di tempo: Day 1
|
Ventilation (VE) will be measured during the Six-Minute Walk Test (6MWT) using the Spiropalm device.
|
Day 1
|
|
Body muscle mass
Lasso di tempo: Day 1
|
Body muscle mass (kg) will be measured using Bioelectrical Impedance Analysis (BIA).
Participants will be informed about the test protocol and instructed to fast for 8-12 hours before the assessment, arrive with an empty bladder, and avoid fluid intake, food consumption, and vigorous physical activity prior to testing.
Measurements will be performed during daytime at a room temperature of 25°C.
Participants will be assessed while clothed and barefoot after removing their shoes, socks, and all metal accessories.
|
Day 1
|
|
Forced expiratory volume in the first second (FEV1)
Lasso di tempo: Day 1
|
Forced expiratory volume in the first second (FEV1) will be evaluated using a Pulmonary Function Test (PFT) in accordance with the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria, utilizing the "COSMED Spiropalm 6MWT" device (COSMED, Italy) and its integrated PFT software (ATS & ERS, 2002).
Assessments will be performed in a seated position with back support.
To minimize the risk of infection, a disposable mouthpiece and filter will be used for each participant.
Values will be recorded both in liters and as percentages (%) of predicted values.
Measurements will be repeated three times, and the best value meeting the measurement standards will be recorded.
|
Day 1
|
|
FEV1/FVC ratio
Lasso di tempo: Day 1
|
FEV1/FVC ratio will be evaluated using a Pulmonary Function Test (PFT) in accordance with the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria, utilizing the "COSMED Spiropalm 6MWT" device (COSMED, Italy) and its integrated PFT software (ATS & ERS, 2002).
Assessments will be performed in a seated position with back support.
To minimize the risk of infection, a disposable mouthpiece and filter will be used for each participant.
Values will be recorded both in liters and as percentages (%) of predicted values.
Measurements will be repeated three times, and the best value meeting the measurement standards will be recorded
|
Day 1
|
|
Peak ventilation (VEpeak)
Lasso di tempo: Day 1
|
Peak ventilation (VEpeak) will be measured during the Six-Minute Walk Test (6MWT) using the Spiropalm device.
|
Day 1
|
|
Peak breathing reserve (BRpeak)
Lasso di tempo: Day 1
|
Peak breathing reserve (BRpeak) will be measured during the Six-Minute Walk Test (6MWT) using the Spiropalm device.
|
Day 1
|
|
Respiratory frequency (RF)
Lasso di tempo: Day 1
|
Respiratory frequency (RF) will be measured during the Six-Minute Walk Test (6MWT) using the Spiropalm device.
|
Day 1
|
|
Inspiratory capacity (IC)
Lasso di tempo: Day 1
|
Inspiratory capacity (IC) will be measured during the Six-Minute Walk Test (6MWT) using the Spiropalm device.
|
Day 1
|
|
Body muscle percentage
Lasso di tempo: Day 1
|
Body muscle percentage (%) will be measured using Bioelectrical Impedance Analysis (BIA).
Participants will be informed about the test protocol and instructed to fast for 8-12 hours before the assessment, arrive with an empty bladder, and avoid fluid intake, food consumption, and vigorous physical activity prior to testing.
Measurements will be performed during daytime at a room temperature of 25°C.
Participants will be assessed while clothed and barefoot after removing their shoes, socks, and all metal accessories.
|
Day 1
|
|
Weight-Adjusted Waist Index (WWI)
Lasso di tempo: Day 1
|
Weight-Adjusted Waist Index (WWI) will be calculated by dividing waist circumference (cm) by the square root of body weight (kg).
|
Day 1
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Stimato)
30 giugno 2026
Completamento primario (Stimato)
20 novembre 2026
Completamento dello studio (Stimato)
15 dicembre 2026
Date di iscrizione allo studio
Primo inviato
8 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
15 maggio 2026
Primo Inserito (Effettivo)
22 maggio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
22 maggio 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
15 maggio 2026
Ultimo verificato
1 maggio 2026
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Obesity2052026
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
INDECISO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Pulmonary Function, Body Composition, and Functional Capacity Assessment
-
Hospices Civils de LyonNon ancora reclutamento